115 related articles for article (PubMed ID: 30486699)
1. Determination of acyclovir in renal microdialysis fluid and confirmation of renal function index.
Shen Z; Yu Q; Li Y; Bao Y; Lu H
Drug Chem Toxicol; 2020 Nov; 43(6):574-580. PubMed ID: 30486699
[TBL] [Abstract][Full Text] [Related]
2. Proteomic characterization of acyclovir-induced nephrotoxicity in a mouse model.
Lu H; Han YJ; Xu JD; Xing WM; Chen J
PLoS One; 2014; 9(7):e103185. PubMed ID: 25055032
[TBL] [Abstract][Full Text] [Related]
3. A metabolic profiling analysis of the nephrotoxicity of acyclovir in rats using ultra performance liquid chromatography/mass spectrometry.
Xing W; Gu L; Zhang X; Xu J; Lu H
Environ Toxicol Pharmacol; 2016 Sep; 46():234-240. PubMed ID: 27497730
[TBL] [Abstract][Full Text] [Related]
4. Hepatic and renal effects of azidothymidine and acyclovir on pregnant rats.
Mamede JA; Oliveira-Filho RM; Simo s MJ; Mora OA; Espiridião SKulay L
Clin Exp Obstet Gynecol; 2000; 27(3-4):227-30. PubMed ID: 11214960
[TBL] [Abstract][Full Text] [Related]
5. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
Katragadda S; Gunda S; Hariharan S; Mitra AK
Int J Pharm; 2008 Jul; 359(1-2):15-24. PubMed ID: 18472234
[TBL] [Abstract][Full Text] [Related]
6. In vivo quantification of acyclovir exposure in the dermis following iontophoresis of semisolid formulations.
Shukla C; Friden P; Juluru R; Stagni G
J Pharm Sci; 2009 Mar; 98(3):917-25. PubMed ID: 18623192
[TBL] [Abstract][Full Text] [Related]
7. The acute toxicity of BIOLF-143 in the rat.
Ecobichon DJ; Mekhael KM; Major P; Ogilvie KK
Fundam Appl Toxicol; 1988 Feb; 10(2):313-20. PubMed ID: 3356318
[TBL] [Abstract][Full Text] [Related]
8. Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique.
Hughes PM; Krishnamoorthy R; Mitra AK
J Ocul Pharmacol Ther; 1996; 12(2):209-24. PubMed ID: 8773936
[TBL] [Abstract][Full Text] [Related]
9. In vivo application of chitosan to facilitate intestinal acyclovir absorption in rats.
Masuda A; Goto Y; Kurosaki Y; Aiba T
J Pharm Sci; 2012 Jul; 101(7):2449-56. PubMed ID: 22535511
[TBL] [Abstract][Full Text] [Related]
10. [Preparation of hepatic targeting antivirus agent NGA-ACV and its targeting property].
Fan JZ; Li TL; Pang QJ; Guan CT; He Y; Su KY
Yao Xue Xue Bao; 1996; 31(8):585-90. PubMed ID: 9772705
[TBL] [Abstract][Full Text] [Related]
11. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits.
Chetoni P; Rossi S; Burgalassi S; Monti D; Mariotti S; Saettone MF
J Ocul Pharmacol Ther; 2004 Apr; 20(2):169-77. PubMed ID: 15117573
[TBL] [Abstract][Full Text] [Related]
12. Famciclovir substitution for patients with acyclovir-associated renal toxicity.
Htwe TH; Bergman S; Koirala J
J Infect; 2008 Sep; 57(3):266-8. PubMed ID: 18656262
[TBL] [Abstract][Full Text] [Related]
13. Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro.
Hostetler KY; Beadle JR; Kini GD; Gardner MF; Wright KN; Wu TH; Korba BA
Biochem Pharmacol; 1997 Jun; 53(12):1815-22. PubMed ID: 9256156
[TBL] [Abstract][Full Text] [Related]
14. Plasma metabolic profiling analysis of nephrotoxicity induced by acyclovir using metabonomics coupled with multivariate data analysis.
Zhang X; Li Y; Zhou H; Fan S; Zhang Z; Wang L; Zhang Y
J Pharm Biomed Anal; 2014 Aug; 97():151-6. PubMed ID: 24863373
[TBL] [Abstract][Full Text] [Related]
15. In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits.
Anand BS; Katragadda S; Gunda S; Mitra AK
Mol Pharm; 2006; 3(4):431-40. PubMed ID: 16889437
[TBL] [Abstract][Full Text] [Related]
16. Topical delivery of different acyclovir palmitate liposome formulations through rat skin in vitro.
Liu H; Pan WS; Tang R; Luo SD
Pharmazie; 2004 Mar; 59(3):203-6. PubMed ID: 15074594
[TBL] [Abstract][Full Text] [Related]
17. Preclinical toxicology studies with acyclovir: acute and subchronic tests.
Tucker WE; Macklin AW; Szot RJ; Johnston RE; Elion GB; de Miranda P; Szczech GM
Fundam Appl Toxicol; 1983; 3(6):573-8. PubMed ID: 6662299
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of acyclovir in rabbit skin after i.v.-bolus, ointment, and iontophoretic administrations.
Stagni G; Ali ME; Weng D
Int J Pharm; 2004 Apr; 274(1-2):201-11. PubMed ID: 15072796
[TBL] [Abstract][Full Text] [Related]
19. Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability.
Tao Y; Lu Y; Sun Y; Gu B; Lu W; Pan J
Int J Pharm; 2009 Aug; 378(1-2):30-6. PubMed ID: 19465102
[TBL] [Abstract][Full Text] [Related]
20. Development of Acyclovir-Loaded Albumin Nanoparticles and Improvement of Acyclovir Permeation Across Human Corneal Epithelial T Cells.
Suwannoi P; Chomnawang M; Sarisuta N; Reichl S; Müller-Goymann CC
J Ocul Pharmacol Ther; 2017 Dec; 33(10):743-752. PubMed ID: 29111864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
